Ayla Annac is an accomplished and entreprenourlal-minded executive. Awarded with Titan 100 CEO, WI in 2024, Annac is the CEO/President Co-Founder of InvivoSciences, Inc. (IVS). (IVS) is a pre-clinical-stage biotech company developing therapies for cardiovascular and cardiometabolic diseases. IVS’s innovation is utilizing its predictive precision medicine technology platform, Kokordia™, combining patient-derived micro heart on a chip, NuHeart™, AI-assisted patient-stratification and clinical trial enrichment /diagnostic technologies, and automated instrumentation for precision medicine development. IVS201 is the company’s lead drug program targeting heart failure with preserved ejection fraction (HFpEF). Annac’s 25 years of strategic business development experience in Fortune 500 companies and technology startups enabled the commercialization of IVS’s pioneering and award-winning technologies for drug discovery and development. IVS’s initial technologies received Gold in the 2012 Edison Award and Gold In the 2009 World’s Best Technologies Award in Texas. Science Magazine also listed IVS among the honorable mentions awards. In 2015, In-Business-Magazine awarded Ms. Annac with a Women of Industry. She was a scholar of 2016 Goldman Sachs 10000 Small Business Program in Babson College, Tong BME Distinguished Entrepreneur Lecturer, and a scholarship recipient for 2017 Springboard rare disease program. She was a Ted.com speaker Oct 2018 in London. https://www.youtube.com/watch?v=XXSxqGYnZ0Y&t=16s